Cobimetinib- and vemurafenib-induced granulomatous dermatitis and erythema induratum: A case report-Reference-Cited by-同舟云学术

Cobimetinib- and vemurafenib-induced granulomatous dermatitis and erythema induratum: A case report

Published:2019-01 Issue: Volume:7 Page:2050313X1984735
ISSN:2050-313X
Container-title:SAGE Open Medical Case Reports
language:en
Short-container-title:SAGE Open Medical Case Reports

Author:

Iafolla Marco AJ¹,Ramsay Jennifer²,Wismer Judy³,McWhirter Elaine¹

Affiliation:

1. Department of Medical Oncology, Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada

2. Department of Pathology and Molecular Medicine, Juravinski Hospital, McMaster University, Hamilton, ON, Canada

3. Department of Dermatology, McMaster University, Hamilton, ON, Canada

Abstract

Metastatic melanoma is an aggressive malignancy. Survival can be increased with the combination of BRAF and MEK inhibition. BRAF inhibitor-induced cutaneous toxicities can be attenuated with MEK inhibition. Here, we describe the first reported case of a patient with metastatic melanoma who developed granulomatous dermatitis and erythema induratum when treated with combination BRAF (vemurafenib) and MEK inhibitor (cobimetinib) therapy and discuss the clinical features and management of dermatologic side-effects secondary to BRAF +/– MEK inhibition.

Publisher

SAGE Publications

Subject

General Medicine

Link

http://journals.sagepub.com/doi/pdf/10.1177/2050313X19847358

Reference23 articles.

1. BRAF and MEK inhibition in melanoma

2. BRAF as therapeutic target in melanoma

3. Melanoma — An Unlikely Poster Child for Personalized Cancer Therapy

4. Prognostic and Clinicopathologic Associations of Oncogenic BRAF in Metastatic Melanoma

5. Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Panniculitis does not predict clinical response in patients with advanced melanoma under targeted therapy;European Journal of Dermatology;2023-04

2. Tuberculids: A narrative review;Indian Dermatology Online Journal;2023

3. BRAF inhibition and the spectrum of granulomatous reactions;Journal of the American Academy of Dermatology;2021-10

4. The diagnosis and management of sarcoid-like reactions in patients with melanoma treated with BRAF and MEK inhibitors. A case series and review of the literature;Therapeutic Advances in Medical Oncology;2021-01

5. MAPK blockade, toxicities, pathogenesis and management;Current Opinion in Oncology;2020-12-30